<?xml version="1.0" ?>
<document id="f243e05a2d51029218e0c313b20fa57c65104a62">
  <chunk id="f243e05a2d51029218e0c313b20fa57c65104a62.c0" text="Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications"/>
  <chunk id="f243e05a2d51029218e0c313b20fa57c65104a62.c1" text="The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S. Food and Drug Administration (FDA)-approved drug that blocks EBOV entry and infection in cells and significantly protects EBOV-challenged mice. As provided, clomiphene is, approximately, a 60:40 mixture of two stereoisomers, enclomiphene and zuclomiphene. The pharmacokinetic properties of the two isomers vary, but both accumulate in the eye and male reproductive tract, tissues in which EBOV can persist. Here we compared the ability of clomiphene and its isomers to inhibit EBOV using viral-like particle (VLP) entry and transcription/replication-competent VLP (trVLP) assays. Clomiphene and its isomers inhibited the entry and infection of VLPs and trVLPs with similar potencies. This was demonstrated with VLPs bearing the glycoproteins from three filoviruses (EBOV Mayinga, EBOV Makona, and Marburg virus) and in two cell lines (293T/17 and Vero E6). Visual problems have been noted in EBOV survivors, and viral RNA has been isolated from semen up to nine months post-infection. Since the clomiphene isomers accumulate in these affected tissues, clomiphene or one of its isomers warrants consideration as an anti-EBOV agent, for example, to potentially help ameliorate symptoms in EBOV survivors. 2 of 15 basis; these included the ZMapp cocktail of monoclonal antibodies [7, 8] , hyperimmune serum [9,10], and several low molecular weight anti-viral drugs [11] [12] [13] . Additional therapeutic antibodies [14] [15] [16] [17] have recently been described, and two novel low molecular weight viral RNA polymerase inhibitors are in development [18, 19] . A different approach has been to screen U.S. Food and Drug Administration (FDA)-approved drugs for anti-EBOV activity, with the goal of repurposing an approved drug, or combination of approved drugs, for use as a prophylactic and/or therapeutic in the advent of a future outbreak [20] [21] [22] [23] [24] . Clomiphene surfaced in two independent screens of FDA-approved drugs for anti-EBOV activity [20] [21] [22] ; it blocks EBOV entry and infection in tissue culture cells and provides up to 90% protection in the mouse model of EBOV disease [20, 21] . Clomiphene is a selective estrogen receptor modulator that is used to treat female infertility due to anovulation [25] [26] [27] . It was also proposed in 1991 as a drug to reverse impotence in men due to low testosterone levels [28] , and is currently used off-label for men with hypogonadism. We found, however, that clomiphene exerts its anti-EBOV activity in cell cultures irrespective of expression of the estrogen receptor alpha and/or beta subunits [20] . Instead, clomiphene likely exerts its anti-EBOV activity because it is a cationic amphiphilic drug [29] that accumulates in endolysosomes, the site of EBOV fusion and cytoplasmic entry [30] [31] [32] . Similar to other cationic amphiphilic drugs [29, 33] , clomiphene blocks a late step in the complex process by which the EBOV genome gains access to the host cell cytoplasm to initiate replication, most likely by blocking fusion between the EBOV and endolysosomal membranes [29] .">
    <entity charOffset="637-640" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e0" ontology_id="GO_0000943" text="VLP" type="gene_function"/>
    <entity charOffset="688-691" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e1" ontology_id="GO_0000943" text="VLP" type="gene_function"/>
    <entity charOffset="1162-1170" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e2" ontology_id="HP_0032320" text="affected" type="phenotype"/>
    <entity charOffset="2319-2337" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e3" ontology_id="HP_0008222" text="female infertility" type="phenotype"/>
    <entity charOffset="2326-2337" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e4" ontology_id="HP_0000789" text="infertility" type="phenotype"/>
    <entity charOffset="2424-2433" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e5" ontology_id="HP_0000802" text="impotence" type="phenotype"/>
    <entity charOffset="3061-3070" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e6" ontology_id="GO_0043657" text="host cell" type="gene_function"/>
    <entity charOffset="3061-3080" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e7" ontology_id="GO_0030430" text="host cell cytoplasm" type="gene_function"/>
    <entity charOffset="3071-3080" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e8" ontology_id="GO_0005737" text="cytoplasm" type="gene_function"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e0" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e2" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p0" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e0" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e3" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p1" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e0" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e4" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p2" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e0" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e5" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p3" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e1" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e2" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p4" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e1" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e3" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p5" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e1" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e4" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p6" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e1" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e5" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p7" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e2" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e6" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p8" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e2" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e7" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p9" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e2" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e8" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p10" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e3" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e6" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p11" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e3" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e7" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p12" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e3" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e8" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p13" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e4" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e6" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p14" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e4" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e7" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p15" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e4" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e8" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p16" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e5" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e6" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p17" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e5" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e7" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p18" relation="true"/>
    <pair e1="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e5" e2="f243e05a2d51029218e0c313b20fa57c65104a62.c1.e8" id="f243e05a2d51029218e0c313b20fa57c65104a62.c1.p19" relation="true"/>
  </chunk>
  <chunk id="f243e05a2d51029218e0c313b20fa57c65104a62.c2" text="Clomiphene citrate, the clinically-administered drug and the formulation tested to date for anti-EBOV activity, is a mixture of two diastereoisomers:~60% trans-clomiphene (enclomiphene) and 40% cis-clomiphene (zuclomiphene). Whereas enclomiphene exhibits high anti-estrogenic properties, zuclomiphene does not [34] [35] [36] . The two isomers also differ in other pharmacokinetic properties. For examples, zuclomiphene has a longer half-life in serum [37, 38] and persists in most tissues for longer periods of time than enclomiphene [39] . It could, therefore, be proposed that zuclomiphene is the major contributor to adverse side effects seen in individuals given clomiphene citrate and, conversely, that enclomiphene would impart fewer side effects [39, 40] . Due to these features, as well as its ability to raise testosterone levels, enclomiphene is currently in clinical development as a treatment for secondary hypogonadism (low testosterone levels) [41] .">
    <entity charOffset="919-931" id="f243e05a2d51029218e0c313b20fa57c65104a62.c2.e0" ontology_id="HP_0000135" text="hypogonadism" type="phenotype"/>
  </chunk>
  <chunk id="f243e05a2d51029218e0c313b20fa57c65104a62.c3" text="Because of the differing pharmacological features of enclomiphene and zuclomiphene and the ongoing clinical development of enclomiphene, we compared the effects of clomiphene and its isomers on EBOV entry and replication. We found that clomiphene, enclomiphene, zuclomiphene, and two of their primary metabolites (4-hydroxy-enclomiphene and 4-hydroxy-zuclomiphene) block EBOV entry and replication to similar levels. Compared to clomiphene, enclomiphene, and zuclomiphene displayed similar dose profiles for blocking EBOV entry and replication, as tested in two cell types and with the glycoproteins from two isolates of EBOV as well as from a Marburg virus."/>
</document>
